Undifferentiated carcinoma of the endometrium: a review
References (20)
- et al.
Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases
Gynecol Oncol
(2003) - et al.
Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophos- mamide (pAc)
Gynecol Oncol
(1992) - et al.
Evaluation of unfavorable histologic subtypes in endometrial adenocarcinoma
Am J Obstet Gynecol
(1990) - et al.
Undifferentiated carcinoma of the endometrium
Am J Surg Pathol
(2005) - et al.
Indicators of prognosis in carcinoma of the corpus uteri
Surg Gynecol Obstet
(1969) - et al.
The prognostic value of nuclear grading and the revised FIGO grading of endometrial adenocarcinoma
Int J Gynecol Pathol
(2002) Pathologic indicators of prognosis in endometrial adenocarcinoma: selected aspects emphasizing the GOG experience
Pathol Ann
(1995)- et al.
Endometrial carcinoma
- et al.
Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma
Am J Surg Pathol
(1982) - et al.
Low-stage clear-cell carcinoma of the endometrium
Am J Surg Pathol
(1995)
Cited by (112)
Uncommon and Difficult High-Grade Endometrial Carcinomas
2022, Surgical Pathology ClinicsCitation Excerpt :It was next recognized that undifferentiated carcinoma can be associated with low-grade endometrioid carcinoma, in which case the term “dedifferentiated carcinoma” applies.2 Before the 2020 WHO classification of female genital tract tumors, dedifferentiated carcinoma was strictly defined as composed of undifferentiated carcinoma and a low-grade endometrioid carcinoma (FIGO grade 1 or 2) components.1–4 It is now recognized that dedifferentiated carcinoma can also arise in the background of high-grade endometrial carcinoma.
Undifferentiated and dedifferentiated neoplasms of the female genital tract
2021, Seminars in Diagnostic PathologyCitation Excerpt :In contrast, extrauterine disease is noted in 30% of FIGO grade 3 endometrioid adenocarcinomas while disease-related death occurs in 39% of patients.2 Conventional chemotherapy regimens have shown minimal value in the treatment of UC.4 One patient responded to radiation therapy and was disease-free at 104 months,4 but studies evaluating the efficacy of radiation are overall limited.
Clinico-pathological significance of TCGA classification and SWI/SNF proteins expression in undifferentiated/dedifferentiated endometrial carcinoma: A possible prognostic risk stratification
2021, Gynecologic OncologyCitation Excerpt :From a molecular point of view, a lineage-specific mutational clustering has not been described, as well no overt cell lineage differentiation has been attributed. The loss of differentiation in UDC/DDEC is often demonstrated immunohistochemically by the loss of expression of epithelial and gynaecological markers [1–4]. Molecularly, the loss of differentiation has been associated to different genetic pathways.
SWI/SNF-deficient malignancies of the female genital tract
2021, Seminars in Diagnostic PathologyCitation Excerpt :UEC may express CD34 (otherwise rarely positive in carcinomas) and cyclin D1 limiting the usefulness of these markers in the differential diagnosis with proximal type epithelioid sarcoma and YWHAE-NUTM2 rearranged high-grade endometrial stromal sarcoma, respectively.42,43 As noted previously, a characteristic feature of UEC (and the undifferentiated component of DEC) is loss of expression of the more specific differentiation markers PAX8, ER and PR.17,20,21 As with SWI/SNF complex proteins and epithelial marker expression, loss of staining is usually restricted to the undifferentiated component of DEC with retained expression in the differentiated element.